Takeda Accelerates Access to its Dengue Vaccine Through 'Make in India' Manufacturing Partnership with Biological E.
* New strategic partnership will scale-up manufacturing capacity to support global supply of dengue vaccine and expands Takeda's footprint in vaccine manufacturing. * The strategic partnership will deliver potentially up to 50 million doses per year by 2030 to address global public health n...
OrigiMed and Takeda Announced Partnership to Accelerate R&D and Commercialization of Innovative Medicines
* The collaboration will develop an innovative genomic-based clinical treatment platform * The goal of the collaboration is to accelerate the R&D and commercialization of innovative medicines SHANGHAI, Nov. 11, 2020 /PRNewswire/ --OrigiMed, a China-based leading precision medicine company and...
Takeda Issues US Recall of NATPARA® (parathyroid hormone) for Injection Due to the Potential for Rubber Particulate
Patients are advised to immediately consult their healthcare providers to help ensure safe discontinuation of NATPARA treatment Takeda is working closely with the US Food and Drug Administration (US FDA) to resolve the issue and resume supply as soon as possible OSAKA, Japan, Sept. 6, 2019 /PRNe...
Takeda, Microsoft and EURORDIS release report with action plan to help rare disease community shorten the diagnostic odyssey
Global Commission's recommendations focus on three solution pathways that leverage technology toaddress key elements of the rare disease diagnostic odyssey Rare diseases remain undiagnosed as patients struggle to navigate complex health systems to receive accurate diagnoses, which can take an av...
New Post-Hoc Analyses Report Early Symptomatic Improvement in Moderately to Severely Active Ulcerative Colitis or Crohn's Disease Patients Taking Entyvio® (vedolizumab), Particularly in Biologic-Naïve Patients
OSAKA, Japan, Oct. 16, 2017 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (TSE: 4502), ("Takeda") today announced the presentation of data suggesting early symptomatic improvement in specific symptoms with Entyvio® (vedolizumab) in patients with moderately to severely active ulcerative co...
Takeda and Marvel Custom Solutions Debut the Full IBD Unmasked Graphic Novel Featuring a Team of Inflammatory Bowel Disease (IBD) Super Heroes
Two new chapters complete The Unbeatables graphic novel designed to raise
awareness of the unrecognized Super Heroes of the global IBD community
OSAKA, Japan, Aug. 2, 2017 /PRNewswire/ -- Takeda Pharmaceutical Company
Limited[TSE: 4502]
Takeda and Marvel Custom Solutions Launch the Latest Adventure of the IBD Unmasked Super Hero Squad in Celebration of World IBD Day 2017
New chapter of The Unbeatables graphic comic book highlights the strength of
those living with inflammatory bowel disease (IBD)
OSAKA, Japan, May 19, 2017 /PRNewswire/ -- In celebration of World IBD Day,
which takes place every year on 19 May, Takeda Pharmaceutical Company Limited [
TSE: 4502
New Real-World Analyses Support Effectiveness and Safety of Entyvio(R) (vedolizumab) for Ulcerative Colitis and Crohn's Disease
OSAKA, Japan, May 8, 2017 /PRNewswire/ -- Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") today announced the presentation of eight real-world analyses supporting the effectiveness and safety of Entyvio® (vedolizumab) for the treatment of adults with moderately to severely active ul...
Five-Year Open-Label Prospective Study Data Presented at the 12th Congress of European Crohn's and Colitis Organisation (ECCO) Provides Information on the Long-Term Use of Vedolizumab in Adult Patients with Moderate to Severely Active Ulcerative Colitis and Crohn's Disease
Post-hoc data from GEMINI I also presented at ECCO further support a favorable benefit: risk profile for vedolizumab as a treatment option for adult patients with moderate to severely active ulcerative colitis to maintain sustained remission OSAKA, Japan, Feb. 17, 2017 /PRNewswire/ -- Takeda Pha...
GEMINI II & III Post-hoc Analysis Reports Clinical Benefits of Vedolizumab
OSAKA, Japan, Dec. 9, 2016 /PRNewswire/ -- Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") announced that an analysis based on pre-specified and post-hoc exploratory outcomes of GEMINI II and GEMINI III data evaluating Entyvio (vedolizumab) therapy in patients with moderately to se...
Takeda Unmasks Four New Super Heroes at London's Comic Con to Highlight the Strength of those Living with Inflammatory Bowel Disease (IBD) with the Support of Marvel Custom Solutions
OSAKA, Japan, Oct. 28, 2016 /PRNewswire/ -- Takeda Pharmaceutical Company
Limited (TSE: 4502
Takeda's Vedolizumab Demonstrated Robust Clinical Effectiveness and Safety in Inflammatory Bowel Disease in More Than 50 Real-World Studies
OSAKA, Japan, Oct. 17, 2016 /PRNewswire/ -- Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") is presenting data on the real-world effectiveness and safety of vedolizumab in patients with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD) during the United ...
Additional Interim Data Supporting Long-Term Use of Vedolizumab in Patients with Ulcerative Colitis and Crohn's Disease Published in Journal of Crohn's and Colitis
OSAKA, Japan, Sept. 29, 2016 /PRNewswire/ -- Takeda Pharmaceutical Company
Limited[TSE: 4502]
Favorable Benefit: Risk Profile for Vedolizumab as Induction and Maintenance Therapy in TNF-Naïve or TNF-Failure Patients with Moderately to Severely Active Ulcerative Colitis Published in Clinical Gastroenterology and Hepatology
OSAKA, Japan, Sept. 18, 2016 /PRNewswire/ -- Takeda Pharmaceutical Company
Limited[TSE: 4502],
Takeda and TiGenix Announce Publication in The Lancet of 24-Week Results of the Phase 3 ADMIRE-CD Trial Investigating Cx601 in the Treatment of Complex Perianal Fistulas in Patients with Crohn's Disease
OSAKA, Japan and LEUVEN, Belgium, Aug. 2, 2016 /PRNewswire/ -- Takeda
Pharmaceutical Company Limited (TSE: 4502
IBD Unmasked, a First-of-its-Kind Global Awareness Initiative, Launches to Support and Empower the Inflammatory Bowel Disease Community
OSAKA, Japan, July 13, 2016 /PRNewswire/ -- Takeda unveils new IBD S uper H ero and graphic illustrations, developed in collaboration with Marvel Custom Solutions, to highlight the strength of and inspire confidence in those living with IBD If someone with inflammatory bowel disease (...
Takeda and TiGenix Enter into Licensing Agreement for Ex-U.S. Rights to Cx601 for the Treatment of Complex Perianal Fistulas in Patients with Crohn's Disease
OSAKA, Japan and LEUVEN, Belgium, July 5, 2016 /PRNewswire/ -- Takeda
Pharmaceutical Company Limited (TSE: 4502
EXAMINE Trial Post-Hoc Analyses of Mortality Data Regarding Cardiovascular Safety of Alogliptin Presented at American Diabetes Association's 76th Scientific Sessions and Published in Diabetes Care
OSAKA, Japan, June 12, 2016 /PRNewswire/ -- Takeda Pharmaceutical Company
Limited [TSE: 4502
Takeda Licenses Global Rights to Theravance Biopharma's TD-8954, a Novel 5-HT4 Agonist and Motility Agent for Gastrointestinal Motility Disorders
OSAKA, Japan and DUBLIN, June 8, 2016 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") and Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") today announced that the companies have entered into a global license, development and commercialization agreem...
Takeda to Present New Data at the American Diabetes Association's 76th Scientific Sessions
OSAKA, Japan, June 7, 2016 /PRNewswire/ -- Takeda Pharmaceuticals Company
Limited[TSE: 4502],
